Tempus xR whole transcriptome RNA sequencing for Life Sciences

Overview

Tempus xR is a whole transcriptome RNA-seq panel for solid tumors and hematologic malignancies that reports clinically relevant1 fusions for more than 100 targeted genes,2 as well as altered splicing events for MET exon 14 and EGFRvIII.

Depth of sequencing (average)

50 million reads

Platforms used

Illumina NovaSeq

 

Accepted sample types

FFPE slides, blocks, frozen samples, extracted RNA (RUO), peripheral blood, bone marrow

Alterations identified

Rearrangements, fusions, altered splicing for MET Exon 14 and EGFRvIII

 

Tumor type

Heme and solid

 

Sensitivity

97% for rearrangements/ fusions, 100% for altered splicing (MET Exon 14), 95.5% for altered splicing (EGFRvIII)3

Validation summary

Download xR Validation →

The value of RNA

Powering novel discoveries at every
stage of therapeutic development

 

In addition to fusion detection, RNA-seq offers several advantages to biopharma and researchers—from target discovery and selection through CDx development.

  • Molecular characterization: Characterizing the prevalence or degree of overexpression in late-stage tumors

  • Mechanistic studies: Understanding the pharmacokinetics and pharmacodynamics of novel therapies

  • Predicting drug sensitization and resistance: Identify predictive expression profiles to isolate mechanisms of drug response and resistance

  • Trial recruitment: Screening patients for overexpression of genes to be used as a surrogate for IHC or screening tool to identify patients likely to be IHC+ for multiple tests

  • Clinical design: Combining full genomic and transcriptomic characterization of patients entering a trial to identify molecular signatures of response or resistance to refine biomarker strategy in later phases

  • CDx development: Offers alternatives to traditional CDx biomarkers such as single gene overexpression, transcriptional signatures of pathway activation or immune activity

  • Indication expansion: Retrospective analyze samples to identify label expansion opportunities by selectively identifying cancer types and post-treatment settings with high expression of genes that are targeted by a therapy

  • Real-world market analysis: Pair with treatment records and outcomes data, to quantify the uptake of IHC testing and prescription rates to identify areas for growth and monitor real-world efficacy

Learn more about the value of RNA-seq ↗︎

Our science

Use of clinical RNA-sequencing in the detection of actionable fusions compared to
DNA-sequencing alone

In a pan-cancer analysis (n=2,118) of specific gene fusion events, RNA-seq consistently improved the detection of fusions compared to DNA-seq alone across all cancer types, with 1,106 fusions classified as targetable by OncoKB indication-matched therapies, 19% (214) of which were identifiable through RNA-seq alone, 5% (54) by DNA-seq alone, and 76% (838) identifiable through RNA- and DNA-seq.4

NGS suite

Tempus offers broad panels for both DNA- and RNA-based sequencing
Tempus xR can be ordered standalone or in combination with Tempus xT, providing a comprehensive view of genomic profiles.

  • Tempus xR
    Whole transcriptome RNA sequencing panel

  • Tempus xT
    648 gene DNA sequencing panel, tumor/normal matched

Explore our full suite of NGS assays for every stage of clinical development →

References

  1. Clinically relevant fusions are defined as alterations that are associated with available therapeutic options, prognostic implications, diagnostic relevance, or clinical trial enrollment opportunities for a specific variant identified in a patient’s tumor or hematologic malignancy.
  2. Examples of targeted genes include but are not limited to: ALK, RET, ROS1, NTRK1/2/3, FGFR1/2/3, NRG1, BRAF, EWSR1, PML-RARA, BCR-ABL.
  3. Performance specifications of the Tempus xR assay in Tempus’ Chicago, IL, laboratory. For Durham, NC lab performance specifications, see the xR validation summary.
  4. Michuda J, Park BH, Cummings AL, et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J Clin Oncol. 2022;40(16_suppl):3077

The information on this page is intended for life sciences companies and focuses on research and development applications.

This is AI-enabled precision medicine

This is the future of healthcare.